Niva Bupa Health

Who are the top shareholders of the Niva Bupa Health?

The top shareholders of Niva Bupa Health are Bupa Singapore Holdings Pte Ltd with 55.98%, followed by foreign institutional investors at 8.9%, mutual funds at 2.68%, and individual investors at 4.23%. There are no pledged promoter holdings, reflecting strong promoter commitment.

The top shareholders of Niva Bupa Health include Bupa Singapore Holdings Pte Ltd, which holds a significant 55.98% of the company. The majority of the remaining shares are held by mutual funds, which account for 2.68% across 14 schemes, and foreign institutional investors (FIIs), who hold 8.9% through 42 different entities. Additionally, individual investors collectively own 4.23% of the shares. Notably, there are no pledged promoter holdings, indicating a strong commitment from the promoters.

Has Niva Bupa Health declared dividend?

No Dividend History Available

Who are the peers of the Niva Bupa Health?

Niva Bupa Health's peers include SBI Life Insurance, HDFC Life Insurance, ICICI Prudential Life, ICICI Lombard, Max Financial, and others. It has excellent growth, average management risk, and lacks a 1-year return for comparison, while HDFC Life Insurance leads with a 37.78% return.

Peers: The peers of Niva Bupa Health are Life Insurance, SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, ICICI Lombard, General Insuranc, Max Financial, Go Digit General, New India Assura, and Medi Assist Ser.<BR><BR>Quality Snapshot: Excellent management risk is observed at ICICI Lombard and Medi Assist Ser., while Average management risk is found at Life Insurance, SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, General Insuranc, Max Financial, Go Digit General, and Niva Bupa Health, and Below Average management risk is noted at New India Assura. Growth is Excellent at Niva Bupa Health and Go Digit General, Average growth is seen at SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, ICICI Lombard, General Insuranc, Max Financial, and the rest, while Below Average growth is present at Life Insurance and New India Assura. Capital Structure is Excellent across all peers.<BR><BR>Return Snapshot: The peer with the highest 1-year return is HDFC Life Insur. at 37.78%, while the peer with the lowest 1-year return is New India Assura at -22.35%. Niva Bupa Health does not have a 1-year return available for comparison. Additionally, the peers with negative six-month returns are General Insuranc, New India Assura, and Medi Assist Ser.

Is Niva Bupa Health overvalued or undervalued?

As of November 27, 2024, Niva Bupa Health is considered very expensive and overvalued, with a PE ratio of 71.14 and significant underperformance at -0.62% year-to-date compared to the Sensex's 5.54%.

As of 27 November 2024, the valuation grade for Niva Bupa Health has moved from does not qualify to very expensive. The company is currently considered overvalued, with a PE ratio of 71.14, an EV to EBITDA ratio of 263.82, and a Price to Book Value of 7.37. These metrics significantly exceed those of its peers, such as Life Insurance with a PE ratio of 12.54 and Bajaj Finance Ltd. at 35.01, indicating a stark contrast in valuation.<BR><BR>In comparison to the broader market, Niva Bupa Health has underperformed, with a year-to-date return of -0.62% against the Sensex's 5.54%. This underperformance, coupled with its high valuation ratios, reinforces the conclusion that the company is overvalued in the current market environment.

What does Niva Bupa Health do?

Niva Bupa Health Insurance Company Ltd, originally Max Bupa, is a mid-cap health insurance provider in India, reporting net sales of ₹15,274 Cr and a net profit of ₹2,061 Cr for Q1 2025. Key metrics include a P/E ratio of 78.00 and a market cap of ₹16,532 Cr.

Overview:<BR>Niva Bupa Health Insurance Company Ltd operates in the insurance industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was originally incorporated as Max Bupa Health Insurance Limited in 2008. It received its Certificate for Commencement of Business on December 23, 2008. The latest quarterly results reported are for March 2025, showcasing the company's performance in terms of sales and profit.<BR><BR>Financial Snapshot:<BR>- Net Sales: 15,274 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 2,061 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 16,532 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 78.00<BR>- Industry P/E: 23<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.12<BR>- Return on Equity: 10.36%<BR>- Price to Book: 7.95<BR><BR>Contact Details:<BR>No Company Details Available. Registrar Address: Not available.

How big is Niva Bupa Health?

As of 24th July, Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,954.00 Cr, with recent net sales of 4,894.46 Cr and a net profit of 213.52 Cr. The company reported shareholder's funds of 2,982.58 Cr and total assets of 6,191.87 Cr for the latest annual period ending March 2024.

As of 24th July, Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,954.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Niva Bupa reported Net Sales of 4,894.46 Cr and a Net Profit of 213.52 Cr.<BR><BR>For the latest annual period ending March 2024, the company had Shareholder's Funds of 2,982.58 Cr and Total Assets amounting to 6,191.87 Cr.

How has been the historical performance of Niva Bupa Health?

Niva Bupa Health experienced significant growth from March 2024 to March 2025, with net sales rising to 4,894.46 Cr and profit after tax increasing to 213.52 Cr, while total assets grew to 9,760.16 Cr. The company improved its operating profit margin to 1.19% and enhanced cash flow from operating activities to 1,654.00 Cr.

Answer:<BR>The historical performance of Niva Bupa Health shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Niva Bupa Health's net sales increased from 3,811.25 Cr in March 2024 to 4,894.46 Cr in March 2025, while other operating income rose from 304.22 Cr to 479.82 Cr, leading to a total operating income of 5,374.28 Cr, up from 4,115.47 Cr. Total expenditure, excluding depreciation, also increased to 5,316.18 Cr from 4,254.40 Cr, with employee costs rising slightly and manufacturing expenses significantly increasing from 3,000.37 Cr to 4,061.10 Cr. The company turned around its operating profit, achieving 213.52 Cr in March 2025 compared to 81.85 Cr in March 2024, with a notable improvement in operating profit margin from -3.65% to 1.19%. Profit after tax also saw a substantial increase from 81.85 Cr to 213.52 Cr, resulting in a PAT margin growth from 2.15% to 4.36%. On the balance sheet, total assets grew from 6,191.86 Cr to 9,760.16 Cr, driven by an increase in non-current investments from 5,458.23 Cr to 8,175.08 Cr. Shareholder's funds rose significantly from 2,982.62 Cr to 3,776.22 Cr, while total liabilities increased to 9,760.16 Cr from 6,191.86 Cr. Cash flow from operating activities improved to 1,654.00 Cr from 812.00 Cr, although cash flow from investing activities worsened to -2,347.00 Cr from -1,881.00 Cr. The closing cash and cash equivalents increased to 220.00 Cr from 142.00 Cr, reflecting a positive cash flow trend.

Is Niva Bupa Health technically bullish or bearish?

As of November 28, 2025, Niva Bupa Health's technical stance is bearish due to negative indicators like a bearish MACD and moving averages, despite a mildly bullish signal from Dow Theory.

As of 28 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Niva Bupa Health is bearish, with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands and moving averages on the daily timeframe, and a bearish KST on the weekly. Although the Dow Theory indicates a mildly bullish signal on the weekly, it is outweighed by the overall bearish indicators. The stock has underperformed against the Sensex year-to-date and over the past year, further supporting the bearish outlook.

When is the next results date for Niva Bupa Health Insurance Company Ltd?

The next results date for Niva Bupa Health Insurance Company Ltd is January 29, 2026.

The next results date for Niva Bupa Health Insurance Company Ltd is scheduled for January 29, 2026.

Are Niva Bupa Health Insurance Company Ltd latest results good or bad?

Niva Bupa Health Insurance Company's latest results show strong revenue growth with Q2 FY26 net sales up 17.21%, but the company reported a net loss of ₹35.27 crores and negative operating margins, raising concerns about its profitability and sustainability.

Niva Bupa Health Insurance Company Ltd's latest results present a mixed picture. On one hand, the company has shown strong revenue growth, with net sales for Q2 FY26 reaching ₹1,422.05 crores, reflecting a year-on-year increase of 17.21% and a sequential growth of 16.56%. This indicates that the company is successfully capturing market share in a growing health insurance sector.<BR><BR>However, the profitability remains a significant concern. The company reported a net loss of ₹35.27 crores for Q2 FY26, which, while reduced by 61.43% from the previous quarter, still marks the second consecutive quarterly loss in the fiscal year. This raises questions about the sustainability of its growth strategy. The operating margin also remains negative at -3.74%, although it has improved from -7.62% in the previous quarter.<BR><BR>Additionally, the return on equity (ROE) stands at a low 5.00%, which is below the industry average, indicating weak capital efficiency. The cumulative net loss for the first half of FY26 reached ₹126.71 crores, a stark contrast to the modest loss of ₹5.80 crores in the same period last year.<BR><BR>In summary, while Niva Bupa is achieving notable revenue growth, its ongoing losses and challenges in achieving profitability overshadow these positive aspects, making the overall results appear concerning.

Should I buy, sell or hold Niva Bupa Health Insurance Company Ltd?

Why is Niva Bupa Health Insurance Company Ltd falling/rising?

As of 02-Apr, Niva Bupa Health Insurance Company Ltd's stock price has risen to 72.56, reflecting a 0.37% increase, driven by strong fundamentals and recent performance despite some negative indicators. The stock has outperformed its sector and shown positive growth, although concerns about valuation and quarterly results remain.

As of 02-Apr, Niva Bupa Health Insurance Company Ltd is experiencing a rise in its stock price, currently at 72.56, with a change of 0.27 (0.37%) upward. This increase can be attributed to several factors. The stock has outperformed its sector by 8.81% today and has shown a consecutive gain over the last three days, rising by 3.66% during this period. Additionally, the stock's performance over the past week has been positive, with a return of +1.75%, contrasting sharply with the Sensex, which has fallen by -2.60%.<BR><BR>Despite some negative indicators, such as a significant drop in delivery volume and the stock trading below longer-term moving averages, the strong long-term fundamental strength of the company is noteworthy. The company has demonstrated impressive growth in operating profits, with a compound annual growth rate (CAGR) of 160.87%, and net sales have increased at an annual rate of 30.60%. Furthermore, high institutional holdings at 26.36% suggest that knowledgeable investors are backing the stock, which can provide a level of confidence in its potential.<BR><BR>However, it is important to note that there are also significant concerns, including a flat performance in recent quarterly results and a negative EBITDA, indicating that the stock is trading at a risky valuation compared to its historical averages. Despite these risks, the recent upward movement in stock price reflects a short-term positive sentiment among investors, likely driven by the company's strong fundamentals and recent performance relative to the sector.

Which are the latest news on Niva Bupa Health?